IN8bio To Make Nasdaq Debut On July 30

pharma 032017 13jun21 lt

IN8bio, Inc., founded in 2016, is making its NASDAQ debut today (Jul.30, 2021), under the ticker symbol "INAB".

The New York, IN8bio, formerly Incysus Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for the treatment of cancer.

The company has offered to sell 4.0 million Shares of common stock at a price of $10 per share. The underwriters have a 30-day option to purchase up to an additional 600,000 shares.

The aggregate gross proceeds are expected to be approximately $40 million. The offering is scheduled to close on August 3, 2021.

Underwriters of the IPO:

B. Riley Securities, Inc.

Pipeline and Near-term Catalysts:

Its lead candidates INB-200, currently in a Phase 1 trial for newly diagnosed glioblastoma or GBM, for which initial results from the second cohort in this Phase 1 trial is expected by the end of 2021 and from the third cohort in 2022.

INB-100, currently in a Phase 1 trial for patients with leukemia undergoing hematopoietic stem cell transplantation or HSCT, with initial results from the first cohort is expected in 2022, with topline results for all cohorts in 2023.

INB-400, an allogeneic DeltEx therapeutic candidates for solid tumor cancers, under preclinical testing, and the submission of IND is expected in the first half of 2022.

INB-300, in preclinical program, developing DeltEx DRI product candidates with an added CAR, for certain brain tumors and other solid tumor cancers.

For comments and feedback contact: editorial@rttnews.com

Follow RTT